UB Paderborn / Katalog / Suche / in CDI

Multiple effects of benzamide antibiotics on FtsZ function

Molecular microbiology, 2011-04, Vol.80 (1), p.68-84

2011

Volltextzugriff (PDF)

Modic changes as seen on MRI are associated with nonspecific chronic lower back pain and disability

Journal of orthopaedic surgery and research, 2023-05, Vol.18 (1), p.351-351, Article 351

2023

Volltextzugriff (PDF)

An Improved Small-Molecule Inhibitor of FtsZ with Superior In Vitro Potency, Drug-Like Properties, and In Vivo Efficacy

Antimicrobial Agents and Chemotherapy, 2013-01, Vol.57 (1), p.317-325

2013

Volltextzugriff (PDF)

Pyridine-3-carboxamide-6-yl-ureas as novel inhibitors of bacterial DNA gyrase: Structure based design, synthesis, SAR and antimicrobial activity

European journal of medicinal chemistry, 2014-10, Vol.86, p.31-38

2014

Volltextzugriff (PDF)

Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZ

Bioorganic & medicinal chemistry letters, 2014-01, Vol.24 (1), p.353-359

2014

Volltextzugriff (PDF)

Reply to a letter to the editor regarding the article, “Chronic low back pain, bacterial infection and treatment with antibiotics. Gilligan CJ, Cohen SP, Fischetti VA, Hirsch JA, Czaplewski LG. Spine J 2021 Feb 18;S1529-9430”

The spine journal, 2021-07, Vol.21 (7), p.1236-1237

2021

Volltextzugriff (PDF)

Biological Evaluation of Benzothiazole Ethyl Urea Inhibitors of Bacterial Type II Topoisomerases

Antimicrobial Agents and Chemotherapy, 2013-12, Vol.57 (12), p.5977-5986

2013

Volltextzugriff (PDF)

Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ

Bioorganic & medicinal chemistry letters, 2009-01, Vol.19 (2), p.524-527

2009

Volltextzugriff (PDF)

Letter to the Editor concerning “Prospective study using anterior approach did not show association between Modic 1 changes and low-grade infection in lumbar spine” by Rigal J, Thelen T, Byrne F, Cogniet A, Boissière L, Aunoble S, Le Huec JC (Eur Spine J [2016]; 25(4):1000–5. doi: 10.1007/s00586-016-4396-5)

European spine journal, 2016-10, Vol.25 (10), p.3379-3380

Czaplewski, Lloyd G.

2016

Volltextzugriff (PDF)

Novel Inhibitors of Bacterial Cytokinesis Identified by a Cell-based Antibiotic Screening Assay

The Journal of biological chemistry, 2005-12, Vol.280 (48), p.39709-39715

2005

Volltextzugriff (PDF)

Chronic low back pain, bacterial infection and treatment with antibiotics

The spine journal, 2021-06, Vol.21 (6), p.903-914

2021

Volltextzugriff (PDF)

Inhibitor of FtsZ with Potent and Selective Anti-Staphylococcal Activity

Science (American Association for the Advancement of Science), 2008-09, Vol.321 (5896), p.1673-1675

2008

Volltextzugriff (PDF)

Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors

Bioorganic & medicinal chemistry letters, 2013-12, Vol.23 (24), p.6598-6603

2013

Volltextzugriff (PDF)

DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity

Bioorganic & medicinal chemistry letters, 2009-02, Vol.19 (3), p.894-899

2009

Volltextzugriff (PDF)

Reply to a letter to the editor regarding “Chronic low back pain, bacterial infection and treatment with antibiotics”

The spine journal, 2021-07, Vol.21 (7), p.1231-1232

2021

Volltextzugriff (PDF)

Intradiscal pharmacokinetics of oral antibiotics to treat Chronic Lower Back Pain

NPJ ANTIMICROBIALS AND RESISTANCE, 2023-05, Vol.1 (1), Article 1

2023

Volltextzugriff (PDF)

Aggregation of RANTES Is Responsible for Its Inflammatory Properties

The Journal of biological chemistry, 1999-09, Vol.274 (39), p.27505-27512

1999

Volltextzugriff (PDF)

Aggregation of RANTES is responsible for its inflammatory properties. Characterization of nonaggregating, noninflammatory RANTES mutants

The Journal of biological chemistry, 1999-09, Vol.274 (39), p.27505-27512

1999

Volltextzugriff (PDF)

Identification of Amino Acid Residues Critical for Aggregation of Human CC Chemokines Macrophage Inflammatory Protein (MIP)-1 alpha , MIP-1 beta , and RANTES: Characterization of Active Disaggregated Chemokine Variants

The Journal of biological chemistry, 1999-06, Vol.274 (23), p.16077-16084

1999

Volltextzugriff (PDF)

Corrigendum to “DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity” [Bioorg. Med. Chem. Lett. 19 (2009) 894]

Bioorganic & medicinal chemistry letters, 2009-05, Vol.19 (9), p.2606-2606

2009

Volltextzugriff (PDF)

Corrigendum: Corrigendum to 'DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity' [Bioorg. Med. Chem. Lett. 19 (2009) 894]

Bioorganic & medicinal chemistry letters, 2009-05, Vol.19 (9), p.2606-2606

2009

Volltextzugriff (PDF)

A randomized phase II-study of BB-10010 (macrophage inflammatory protein-1α) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy

Blood, 1998-09, Vol.92 (5), p.1532-1540

1998

Volltextzugriff (PDF)

Assays for macrophage inflammatory proteins

Methods in Enzymology, 1997, Vol.287, p.127-148

1997

Volltextzugriff (PDF)

The effect of the chemokine rhMIP‐1α, and a non‐aggregating variant BB‐10010, on blast cells from patients with acute myeloid leukaemia

British journal of haematology, 1996-10, Vol.95 (1), p.77-84

1996

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Multiple effects of benzamide antibiotics on FtsZ function

Modic changes as seen on MRI are associated with nonspecific chronic lower back pain and disability

An Improved Small-Molecule Inhibitor of FtsZ with Superior In Vitro Potency, Drug-Like Properties, and In Vivo Efficacy

Pyridine-3-carboxamide-6-yl-ureas as novel inhibitors of bacterial DNA gyrase: Structure based design, synthesis, SAR and antimicrobial activity

Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZ

Reply to a letter to the editor regarding the article, “Chronic low back pain, bacterial infection and treatment with antibiotics. Gilligan CJ, Cohen SP, Fischetti VA, Hirsch JA, Czaplewski LG. Spine J 2021 Feb 18;S1529-9430”

Biological Evaluation of Benzothiazole Ethyl Urea Inhibitors of Bacterial Type II Topoisomerases

Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ

Novel Inhibitors of Bacterial Cytokinesis Identified by a Cell-based Antibiotic Screening Assay

Chronic low back pain, bacterial infection and treatment with antibiotics

Inhibitor of FtsZ with Potent and Selective Anti-Staphylococcal Activity

Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors

DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity

Reply to a letter to the editor regarding “Chronic low back pain, bacterial infection and treatment with antibiotics”

Intradiscal pharmacokinetics of oral antibiotics to treat Chronic Lower Back Pain

Aggregation of RANTES Is Responsible for Its Inflammatory Properties

Aggregation of RANTES is responsible for its inflammatory properties. Characterization of nonaggregating, noninflammatory RANTES mutants

Identification of Amino Acid Residues Critical for Aggregation of Human CC Chemokines Macrophage Inflammatory Protein (MIP)-1 alpha , MIP-1 beta , and RANTES: Characterization of Active Disaggregated Chemokine Variants

Corrigendum to “DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity” [Bioorg. Med. Chem. Lett. 19 (2009) 894]

Corrigendum: Corrigendum to 'DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity' [Bioorg. Med. Chem. Lett. 19 (2009) 894]

A randomized phase II-study of BB-10010 (macrophage inflammatory protein-1α) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy

A Randomized Phase-II Study of BB-10010 (Macrophage Inflammatory Protein- 1) in Patients With Advanced Breast Cancer Receiving 5-Fluorouracil, Adriamycin, and Cyclophosphamide Chemotherapy

Assays for macrophage inflammatory proteins

The effect of the chemokine rhMIP‐1α, and a non‐aggregating variant BB‐10010, on blast cells from patients with acute myeloid leukaemia

Suchergebnisse filtern